SCHEMBL19233183

SCHEMBL19233183

CC(C)(C)OC(=O)Nc1c(F)ccc(NC(=O)OCc2ccccc2)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
SYK P43405 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.43
TOP2A P11388 1/20 0.42
TOP2B Q02880 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.41
MGLL Q99685 2/20 0.41
MAOB P27338 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31455060 0.86 NPC1 (0.55) NPC1RAB9ASYKSMN1; SMN2TOP2A
SCHEMBL13193091 0.82 MGLL (0.51) NPC1RAB9ASYKSMN1; SMN2TOP2A
SCHEMBL20578044 0.81 CYP17A1 (0.42) NPC1RAB9ASYKALDH1A1POLB
SCHEMBL7008912 0.80 NPC1 (0.59) NPC1RAB9ASMN1; SMN2POLBMGLL
SCHEMBL8253191 0.78 SYK (0.50) NPC1RAB9ASYKPOLBMEN1
SCHEMBL7043026 0.78 POLB (0.62) NPC1RAB9ASYKSMN1; SMN2TOP2A
SCHEMBL19233248 0.78 CYP17A1 (0.40) NPC1RAB9ASYKPOLBMEN1
SCHEMBL19233270 0.78 NPC1 (0.48) NPC1RAB9ASMN1; SMN2POLBMGLL
SCHEMBL19194842 0.77 NPC1 (0.47) NPC1RAB9ASYKTOP2ATOP2B
SCHEMBL15299968 0.76 NPC1 (0.49) NPC1RAB9ASYKSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2020-11-24 US disclosed
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2019-10-03 US disclosed
WO-2017135589-A9 PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF 삼진제약주식회사 2017-10-19 WO disclosed
WO-2017135589-A1 PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF 삼진제약주식회사 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof BRAF, KDR, RAF1 NPC1 4847/4885RAB9A 933/4885SYK 21/4885
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof BRAF, KDR, RAF1 NPC1 4847/4885RAB9A 933/4885SYK 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.